Dyslipidaemia among renal transplant recipients: cyclosporine versus tacrolimus.

The Journal of the Pakistan Medical Association 2014;64(5):496-9

Aims
To compare the short-term side effects (dyslipidaemia) of cyclosporine versus tacrolimus in renal transplant recipients after 3 months of therapy

Interventions
Patients were randomized to receive either cyclosporine (3mg/kg bodyweight) or tacrolimus (0.1mg/kg body weight).

Participants
182 living-related renal transplant recipients aged 30.18 ± 9.57 years

Outcomes
The primary outcome measured was incidence and frequency of dyslipidaemia. Fasting lipid profiles were also measured.

Follow-up
3 months

CET Conclusions
This is a single-centre study from Pakistan comparing Tacrolimus with Cyclosporine together with azathioprine and prednisolone in living-related kidney transplant recipients. After 3 months there was no difference in dyslipidaemia, elevated total cholesterol, elevated serum triglycerides, reduced serum HDL cholesterol or elevated serum LDL cholesterol. The analysis excluded 8% of the study population because their serum creatinine >1.5mg/dl.

Jadad score
1

Data analysis
Per protocol analysis

Allocation concealment
No

Trial registration
None

Funding source
Not reported